Intervention: Artefenomel
Trial phase: Phase 2
SMILES: c1cc([C@H]2CC[C@]3(CC2)OOC2(O3)C3CC4CC(C3)CC2C4)ccc1OCCN1CCOCC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Single dose of 500mg of OZ439 administered as an oral suspension
Eligibility criteria:
Inclusion Criteria:

Male or female patients between the age of 18 and 60 years, inclusive
Body weight between 45 kg and 90 kg inclusive

Presence of mono-infection of P. falciparum confirmed by:

Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,
Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood.
Written informed consent, in accordance with local practice, provided by patient. If the patient is unable to write, witnessed consent is permitted according to local ethical considerations
Ability to swallow oral medication
Ability and willingness to participate and access the health facility
Agree to hospitalization for at least 72h until parasites have fallen below the level of polymerase chain reaction (PCR) detection and have no signs or symptoms of malaria; and then to return once daily to the study centre for blood sampling for quantitative polymerase chain reaction (qPCR), and rehospitalisation when qPCR levels are detectable.

Exclusion Criteria:

Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2010
Mixed Plasmodium infection
Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day
Presence of other serious or chronic clinical condition requiring hospitalization
Severe malnutrition (defined as the weight-for-height being below -3 standard deviation or less than 70% of median of the NCHS/WHO normalized reference values)
Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater than or equal to 450 msec), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma)
Known history of hypersensitivity, allergic or adverse reactions to artemisinin containing compounds or mefloquine
Known active Hepatitis A Immunoglobulin M (IgM) (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab)
Have received any antimalarial treatment in the preceding 14 days, as determined by history and screening test
Have received antibacterial with known antimalarial activity in the preceding 14 days
Have received an investigational drug within the past 4 weeks
Liver function tests (Aspartate Aminotransferase(ASAT)/Alanine Aminotransferase (ALAT) levels) > 2x upper limit of normal (ULN) if Total Bilirubin normal or >1.5xULN if Total bilirubin between >1 and >1.5xULN
Hemoglobin (Hb) level =< 8g/dl
Total Bilirubin > 1.5XULN
Serum creatinine levels more than 2 times the upper limit of normal range (>2xULN).
Female patients must be neither pregnant as demonstrated by a negative serum pregnancy test at screening and urinary pregnancy test pre-dose (the result of the pre-dose assessment must be confirmed negative prior to dosing) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period.